FDA Approves SKINVIVE by JUVÉDERM for Neck Lines, Expanding AbbVie's Aesthetics Portfolio
ABBV sits 22% above its 52-week low of $181.73.
Summary
AbbVie's Allergan Aesthetics unit secured FDA approval for SKINVIVE by JUVÉDERM® to treat horizontal neck lines, including those from 'tech-neck.' This is the second indication for the hyaluronic acid injectable, which was previously approved for cheek smoothness. The approval provides a new, unique treatment option for neck wrinkles, bolstering AbbVie's presence in the aesthetic market.
At the time of this announcement, ABBV was trading at $221.98 on NYSE in the Life Sciences sector, with a market capitalization of approximately $391.5B. The 52-week trading range was $181.73 to $244.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.